Does anybody think the SHORE trial is going to show anything better Top Line?
I appreciate it’s a bit of a crystal ball gaze - but I’m
sure there are those on here who have a considered view on Ranibzumab versus Aflibercert as a combination agent and as a SOC.
Add to My Watchlist
What is My Watchlist?